CO2023016037A2 - Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos - Google Patents

Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Info

Publication number
CO2023016037A2
CO2023016037A2 CONC2023/0016037A CO2023016037A CO2023016037A2 CO 2023016037 A2 CO2023016037 A2 CO 2023016037A2 CO 2023016037 A CO2023016037 A CO 2023016037A CO 2023016037 A2 CO2023016037 A2 CO 2023016037A2
Authority
CO
Colombia
Prior art keywords
antibodies
tigit
methods
molecules
multispecific
Prior art date
Application number
CONC2023/0016037A
Other languages
English (en)
Inventor
Dhan Sidhartha Chand
Zahra Jawad
Olga Ignatovich
Nicola Anne Ramsay
Spencer Campbell
Beth Wensley
Emmanuel Cyrille Pascal Briend
K Mark Bushell
Benjamin Maxime Morin
Veronica Franciszka Ilkow
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Publication of CO2023016037A2 publication Critical patent/CO2023016037A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente descripción proporciona moléculas multiespecíficas que se unen específicamente a CD96 (por ejemplo, CD96 humano) y/o TIGIT (por ejemplo, TIGIT humano) y anticuerpos aislados que se unen específicamente a TIGIT (por ejemplo, TIGIT humano). También se proporcionan composiciones farmacéuticas que comprenden estas moléculas y anticuerpos multiespecíficos, ácidos nucleicos que codifican estas moléculas y anticuerpos multiespecíficos, vectores de expresión y células hospederas para preparar estas moléculas y anticuerpos multiespecíficos, y métodos para tratar a un sujeto mediante el uso de estas moléculas y anticuerpos multiespecíficos.
CONC2023/0016037A 2021-05-04 2023-11-23 Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos CO2023016037A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163201537P 2021-05-04 2021-05-04
PCT/US2022/072099 WO2022236276A2 (en) 2021-05-04 2022-05-04 Anti-tigit antibodies, anti-cd96 antibodies, and methods of use thereof

Publications (1)

Publication Number Publication Date
CO2023016037A2 true CO2023016037A2 (es) 2023-11-30

Family

ID=83933041

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0016037A CO2023016037A2 (es) 2021-05-04 2023-11-23 Anticuerpos anti-tigit, anticuerpos anti-cd96 y métodos de uso de estos

Country Status (14)

Country Link
US (1) US11718669B2 (es)
EP (1) EP4333893A2 (es)
JP (1) JP2024516843A (es)
KR (1) KR20240006054A (es)
CN (1) CN117425494A (es)
AR (1) AR125753A1 (es)
AU (1) AU2022271331A1 (es)
BR (1) BR112023022319A2 (es)
CA (1) CA3217289A1 (es)
CO (1) CO2023016037A2 (es)
IL (1) IL308157A (es)
PE (1) PE20240369A1 (es)
TW (1) TW202304965A (es)
WO (1) WO2022236276A2 (es)

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5401001B2 (ja) 2002-09-11 2014-01-29 ジェネンテック， インコーポレイテッド 免疫関連疾患の治療のための新規組成物と方法
WO2006124667A2 (en) 2005-05-12 2006-11-23 Zymogenetics, Inc. Compositions and methods for modulating immune responses
SG10201402815VA (en) 2008-04-09 2014-09-26 Genentech Inc Novel compositions and methods for the treatment of immune related diseases
CA3083324A1 (en) 2010-03-05 2011-09-09 The Johns Hopkins University Compositions and methods for targeted immunomodulatory antibodies and fusion proteins
EP2841099A1 (en) 2012-04-26 2015-03-04 Boehringer Ingelheim International GmbH Combination of cd37 antibodies with bendamustine
US9212227B2 (en) * 2012-04-30 2015-12-15 Janssen Biotech, Inc. ST2L antibody antagonists for the treatment of ST2L-mediated inflammatory pulmonary conditions
CA2875980A1 (en) 2012-06-06 2013-12-12 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the hippo pathway and uses thereof
KR20160030936A (ko) 2013-07-16 2016-03-21 제넨테크, 인크. Pd-1 축 결합 길항제 및 tigit 억제제를 사용한 암을 치료하는 방법
WO2017123981A1 (en) 2016-01-15 2017-07-20 Rfemb Holdings, Llc Immunologic treatment of cancer
EP3036258B1 (en) 2013-08-22 2023-07-19 The Council of the Queensland Institute of Medical Research Immunoreceptor modulation for treating cancer and viral infections
US10966998B2 (en) 2013-09-05 2021-04-06 The Johns Hopkins University Cancer therapy via a combination of epigenetic modulation and immune modulation
BR112016006502A2 (pt) * 2013-09-30 2017-09-19 Chugai Pharmaceutical Co Ltd Método para a produção de molécula de ligação de antígeno usando-se fago auxiliar modificado
JP6903432B2 (ja) 2014-03-12 2021-07-14 イエダ リサーチ アンド ディベロップメント カンパニー リミテッド Ｃｎｓの疾患および傷害を処置するために全身性調節性ｔ細胞のレベルまたは活性を低下させること
US20170107300A1 (en) 2014-03-21 2017-04-20 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of immune-related diseases or disorders and/or therapy monitoring
BR112016026299A2 (pt) 2014-05-13 2018-02-20 Chugai Seiyaku Kabushiki Kaisha molécula de ligação ao antígeno redirecionado à célula t para células tendo função de imunossupressão
CN105233291A (zh) 2014-07-09 2016-01-13 博笛生物科技有限公司 用于治疗癌症的联合治疗组合物和联合治疗方法
WO2016011264A1 (en) 2014-07-16 2016-01-21 Genentech, Inc. Methods of treating cancer using tigit inhibitors and anti-cancer agents
IL250583B (en) 2014-08-19 2022-07-01 Merck Sharp & Dohme Anti-tigit antibodies
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
AU2015335607B2 (en) 2014-10-24 2020-04-23 Calidi Biotherapeutics, Inc. Combination immunotherapy approach for treatment of cancer
RU2017119428A (ru) 2014-11-06 2018-12-06 Дженентек, Инк. Комбинированная терапия, включающая применение агонистов, связывающихся с ох40, и ингибиторов tigit
TWI708786B (zh) 2014-12-23 2020-11-01 美商必治妥美雅史谷比公司 針對ｔｉｇｉｔ之抗體
WO2016154544A1 (en) 2015-03-25 2016-09-29 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2016180781A1 (en) 2015-05-08 2016-11-17 Michele Maio Combination therapy of mesothelioma
TWI715587B (zh) 2015-05-28 2021-01-11 美商安可美德藥物股份有限公司 Ｔｉｇｉｔ結合劑和彼之用途
AU2016285920A1 (en) 2015-06-29 2018-02-01 Bristol-Myers Squibb Company Antibodies to CD40 with enhanced agonist activity
AU2016303485A1 (en) 2015-07-31 2018-03-01 Tarveda Therapeutics, Inc. Compositions and methods for immunomodulation
JO3620B1 (ar) 2015-08-05 2020-08-27 Amgen Res Munich Gmbh مثبطات نقطة فحص مناعية للاستخدام في علاج سرطانات محمولة عبر الدم
US10766957B2 (en) 2015-08-14 2020-09-08 Merck Sharp & Dohme Corp Anti-TIGIT antibodies
EA201890630A1 (ru) 2015-09-01 2018-10-31 Эйдженус Инк. Антитела против pd-1 и способы их применения
ES2924071T3 (es) 2015-09-02 2022-10-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Anticuerpos específicos para inmunoglobulina de células T humanas y dominio ITIM (TIGIT)
EP3349792A1 (en) 2015-09-14 2018-07-25 Compass Therapeutics LLC Compositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-
CR20220186A (es) 2015-09-25 2022-07-07 Genentech Inc ANTICUERPOS ANTI-TIGIT Y MÉTODOS DE USO (divisional 2018-0225)
CN108368176B (zh) 2015-10-01 2022-06-07 波滕扎治疗公司 抗tigit抗原结合蛋白及其使用方法
WO2017062619A2 (en) 2015-10-08 2017-04-13 Macrogenics, Inc. Combination therapy for the treatment of cancer
US10421810B2 (en) 2015-10-09 2019-09-24 Lentigen Technology, Inc. Chimeric antigen receptors and methods of use
WO2017152088A1 (en) 2016-03-04 2017-09-08 JN Biosciences, LLC Antibodies to tigit
EP3471752B1 (en) 2016-06-17 2022-03-09 Varian Medical Systems, Inc. Immune modulators in combination with radiation treatment
CA3028721A1 (en) 2016-06-20 2017-12-28 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
EP3617232A1 (en) 2016-08-17 2020-03-04 Compugen Ltd. Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
JP7200093B2 (ja) 2016-09-15 2023-01-06 アイデラ・ファーマシューティカルズ，インコーポレーテッド がん治療用ｔｌｒ９アゴニストを用いた免疫調節
EP3548071A4 (en) 2016-11-30 2020-07-15 OncoMed Pharmaceuticals, Inc. METHOD FOR TREATING CANCER WITH TIGIT-BINDING ACTIVE SUBSTANCES
WO2018102746A1 (en) 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
EP3565839A4 (en) 2017-01-05 2021-04-21 Gensun Biopharma Inc. CHECKPOINT REGULATOR ANTAGONISTS
SG11201907278VA (en) 2017-02-28 2019-09-27 Seattle Genetics Inc Anti-tigit antibodies
JOP20190203A1 (ar) 2017-03-30 2019-09-03 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
EP3618863B1 (en) 2017-05-01 2023-07-26 Agenus Inc. Anti-tigit antibodies and methods of use thereof
RU2019138519A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Стабильные составы антител против tigit, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) 2017-06-20 2017-08-02 Kymab Ltd Antibodies
US20200407445A1 (en) 2017-07-27 2020-12-31 Iteos Therapeutics Sa Anti-tigit antibodies
TWI803523B (zh) 2017-09-29 2023-06-01 大陸商江蘇恆瑞醫藥股份有限公司 Ｔｉｇｉｔ抗體、其抗原結合片段及醫藥用途
TWI758558B (zh) 2017-11-10 2022-03-21 大陸商江蘇恒瑞醫藥股份有限公司 Cd96抗體、其抗原結合片段及醫藥用途
KR20200104333A (ko) 2017-12-28 2020-09-03 난징 레전드 바이오테크 씨오., 엘티디. Tigit에 대한 단일-도메인 항체 및 이의 변이체
TW202400654A (zh) 2017-12-30 2024-01-01 英屬開曼群島商百濟神州有限公司 抗tigit抗體及其作為治療和診斷的用途
US11708410B2 (en) 2018-01-15 2023-07-25 Nanjing Legend Biotech Co., Ltd. Antibodies and variants thereof against TIGIT
WO2019152574A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
KR102224556B1 (ko) 2018-02-06 2021-03-09 아이-맵 바이오파마 유에스 리미티드 Ig 및 itim 도메인을 갖는 t 세포 면역 수용체 (tigit)에 대한 항체 및 이것의 사용
WO2019165434A1 (en) 2018-02-26 2019-08-29 Genentech, Inc. Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
MX2020008795A (es) 2018-02-28 2020-10-08 Yuhan Corp Anti cuerpos anti tigit y usos de los mismos.
CN113286814A (zh) * 2018-10-31 2021-08-20 德里尼亚公司 多价调节性t细胞调节子
EP3938396A1 (en) * 2019-03-11 2022-01-19 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
AU2020308463A1 (en) * 2019-06-26 2022-02-17 Ap Biosciences, Inc. Antibodies for T-cell activation
US11680098B2 (en) 2019-08-30 2023-06-20 Agenus Inc. Antibodies that specifically bind human CD96
EP4333894A1 (en) * 2021-05-04 2024-03-13 Agenus Inc. Anti-tigit antibodies and methods of use thereof

Also Published As

Publication number Publication date
BR112023022319A2 (pt) 2024-02-20
IL308157A (en) 2024-01-01
WO2022236276A2 (en) 2022-11-10
TW202304965A (zh) 2023-02-01
PE20240369A1 (es) 2024-03-04
US20230014036A1 (en) 2023-01-19
AR125753A1 (es) 2023-08-09
US11718669B2 (en) 2023-08-08
CA3217289A1 (en) 2022-11-10
CN117425494A (zh) 2024-01-19
AU2022271331A9 (en) 2023-11-09
WO2022236276A3 (en) 2023-01-19
EP4333893A2 (en) 2024-03-13
AU2022271331A1 (en) 2023-10-26
JP2024516843A (ja) 2024-04-17
KR20240006054A (ko) 2024-01-12

Similar Documents

Publication Publication Date Title
CL2020002314A1 (es) Anticuerpos anti-cd73 y métodos de uso de los mismos
CY1123932T1 (el) Δομες πολυειδικου αντισωματος
CO2018012415A2 (es) Proteínas de unión específica y usos de las mismas
BR112022014667A2 (pt) Anticorpos de domínio único de cd28 e construtos multivalentes e multiespecíficos dos mesmos
BR112019007369A2 (pt) anticorpos anti-lag-3 e métodos de uso dos mesmos
EA201991383A1 (ru) Антитела против ctla-4 и способы их применения
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
CO2019001367A2 (es) Proteínas de unión de tipo anticuerpo biespecíficas que se unen específicamente a cd3 y cd123
EA201892616A1 (ru) Антитела к pd1 и lag3 для лечения злокачественного новообразования
BR112019005316A2 (pt) anticorpos monoclonais para morte programada 1 (pd-1)
AR109276A1 (es) ANTICUERPOS ANTI-hCTLA 4
BR112017007093A2 (pt) composições e métodos de uso para aumento da resposta imune e terapia do câncer
CO2022001977A2 (es) Anticuerpos anti-cd96 y sus métodos de uso
UY37635A (es) Anticuerpos anti phf-tau y sus usos
PE20171764A1 (es) Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecificos que se unen especificamente a cd3 y/o cd123
DOP2015000110A (es) Anticuerpos anti-ceacam5 y usos de estos
BR112018070676A2 (pt) construtos de ligação a antígeno multiespecífico que têm como alvo agentes imunoterapêuticos
AR115389A1 (es) Anticuerpo antagonista de cd73
CL2021000028A1 (es) Anticuerpo multiespecifico (divisional de solicitud 937-2020).
CL2016000438A1 (es) Anticuerpos humanizados que se unen específicamente al receptor del factor estimulante de colonias 1 (csf-1r); ácidos nucleicos; vectores de expresión, células huéspedes; procesos de producción; composiciones farmacéuticas; usos y métodos de tratamiento terapéutico para el tratamiento del cáncer y de la enfermedad fibrótica
BR112017023692A2 (pt) moléculas imunoterapêuticas glican-dependentes
BR112022013236A2 (pt) Anticorpos anti-cd73 e usos dos mesmos
BR112022004047A2 (pt) Proteínas de ligação multiespecíficas para o tratamento de câncer
BR112022011854A2 (pt) Anticorpos, polinucleotídeo isolado, célula hospedeira, métodos para produzir um anticorpo e para tratar uma doença, composição farmacêutica, usos do anticorpo e invenção
CO2020005371A2 (es) Anticuerpos anti-apoc3 y métodos de uso de estos